9月9日からESMO 2022(欧州臨床腫瘍学会)が開催されます。今回は、弊社サイニクスのパートナーであるOracle Life Sciencesのオンコロジースペシャリストおよび弊社サイニクス オンコロジーマーケットアセスメントチームが注目するESMO 2022の講演トピックをお届けします。

ESMO 2022の注目トピック

非小細胞肺がん / Phase 1b/2試験 「MEDI5752」

[LBA56] MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): a Phase 1b/2 trial

乳がん (TNBC) / Phase 2試験 「oleclumab」

[LBA17] Primary endpoint results of SYNERGY, a randomized phase 2 trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)

乳がん (HR陽性) / Phase 3 MONARCH3試験 「abemaciclib」

[LBA15] MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)

乳がん (HR陽性) / Phase 3 TROPiCS-02試験 「sacituzumab govitecan」

[LBA76] Overall survival (OS) results from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

非小細胞肺がん (KRAS G12C変異陽性) / Phase 3 CodeBreaK 200試験 「Sotorasib」

[LBA10] Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

大腸がん / Phase 1/2 KRYSTAL-1試験 「adagrasib (MRTX849)」

[[LBA24] KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation

大腸がん (KRAS G12C変異陽性) / Phase 1b試験 「Sotorasib」

[315O] Sotorasib in combination with panitumumab in refractory KRAS G12Cmutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort